Serum CTRP9 Reflects Coronary Collateralization in Nondiabetic Patients with Obstructive Coronary Artery Disease

Table 1

Basic clinical characteristics of enrolled patients classified by serum CTRP9 level.

CTRP9	Total ()	T1 ()	T2 ()	T3 ()	values
		()	()	()
Demographic data
Age (years)					0.267
Male sex, (%)	174 (84.5%)	58 (84.1%)	56 (81.2%)	60 (88.2%)	0.517
BMI (kg/m^2)					0.384
SBP (mmHg)					0.760
DBP (mmHg)					0.990
HR (bpm)					0.702
Alcohol use, (%)	48 (23.3%)	19 (27.5%)	14 (20.3%)	15 (22.1%)	0.577
Current smokers, (%)	83 (40.3%)	27 (39.1%)	26 (37.7%)	30 (44.1%)	0.723
Types of CAD
UAP, (%)	135 (65.5%)	52 (75.4%)	42 (60.9%)	41 (60.3%)	0.108
SAP, (%)	71 (34.5%)	17 (24.6%)	27 (39.1%)	27 (39.7%)	0.108
Medical history
Hypertension, (%)	132 (64.1%)	47 (68.1%)	44 (63.8%)	41 (60.3%)	0.633
T2DM, (%)	35 (17.0%)	1 (1.4%)	10 (14.5%)	24 (35.3%)	<0.001
Hyperlipidemia, (%)	171 (83.0%)	55 (79.7%)	53 (76.8%)	63 (92.6%)	0.032
MetS, (%)	109 (52.9%)	30 (43.5%)	35 (50.7%)	44 (64.7%)	0.041
Laboratory measurement
MONO					0.226
eGFR					0.110
CREA, mmol/L					0.359
UREA, mmol/L					0.251
UA, mmol/L					0.313
FBG, mmol/L	5.36 (4.92-6.22)	5.36 (5.01-6.09)	5.49 (4.95-6.32)	5.23 (4.77-6.35)	0.684
TC, mmol/L					0.839
TG, mmol/L	1.52 (1.13-2.13)	1.49 (1.07-2.19)	1.53 (1.07-2.03)	1.55 (1.18-2.21)	0.738
HDL-C, mmol/L					0.030
LDL-C, mmol/L					0.703
Non-HDL-C, mmol/L		3.17 ± 0.97	3.27 ± 1.21	3.25 ± 1.25	0.822
Hs-CRP	1.18 (0.65-2.47)	1.29 (0.61-2.91)	1.13 (0.71-2.52)	1.12 (0.66-2.02)	0.811
Cardiovascular medications
Antiplatelet agents, (%)	175 (85.0%)	61 (88.4%)	59 (85.5%)	55 (80.9%)	0.425
ACEI/ARB, (%)	52 (25.2%)	18 (26.1%)	13 (18.8%)	21 (30.9%)	0.284
CCB, (%)	64 (31.1%)	26 (37.7%)	21 (30.4%)	17 (25.0%)	0.277
β receptor blocker, (%)	98 (47.6%)	37 (53.6%)	32 (46.4%)	29 (42.6%)	0.433
Nitrates, (%)	106 (51.5%)	43 (62.3%)	33 (47.8%)	30 (44.1%)	0.084
Statins, (%)	148 (71.8%)	53 (76.8%)	50 (72.5%)	45 (66.2%)	0.364
Coronary angiography data
SYNTAX score					0.119
Number of the diseased vessels					0.644
One-vessel disease, (%)	42 (20.4%)	12 (17.4%)	13 (18.8%)	17 (25.0%)	0.503
Two-vessel disease, (%)	62 (30.1%)	19 (27.5%)	24 (34.8%)	19 (27.9%)	0.581
Three-vessel disease, (%)	102 (49.5%)	38 (55.1%)	32 (46.4%)	32 (47.1%)	0.525
CTO lesions, (%)	104 (50.5%)	27 (39.1%)	39 (56.5%)	38 (55.9%)	0.069
Location of the diseased artery					0.353
RCA, (%)	98 (47.6%)	32 (46.4%)	29 (42.0%)	37 (54.4%)	0.339
LCX, (%)	35 (17.0%)	9 (13.0%)	13 (18.8%)	13 (19.1%)	0.563
LAD, (%)	73 (35.4%)	28 (40.6%)	27 (39.1%)	18 (26.5%)	0.165

indicated the differences between groups were statistically significant. Abbreviations: CTRP9: C1q/tumor necrosis factor-related protein 9; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; CAD: coronary artery disease; UAP: unstable angina pectoris; SAP: stable angina pectoris; T2DM: type II diabetes mellitus; MetS: metabolic syndrome; MONO: monocyte count; eGFR: estimated glomerular filtration rate; CREA: creatinine; UREA: urea; UA: uric acid; FBG: fasting blood glucose; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Hs-CRP: high sensitivity C-reactive protein; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; CTO: chronic total occlusion; RCA: right coronary artery; LCX: left circumflex artery; LAD: left anterior descending artery.